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study assessing the prognostic value of PD-L1 
expression in patients with recurrent and/
or metastatic squamous cell carcinoma 
of the head and neck
Sara I. Pai1* , Ezra E. W. Cohen2, Derrick Lin1,3, George Fountzilas4, Edward S. Kim5, Holger Mehlhorn6, 
Neus Baste7, Daniel Clayburgh8, Loren Lipworth9, Carlo Resteghini10, Nawar Shara11, Takashi Fujii12, 
Jun Zhang13, Michael Stokes14, Huifen Wang15, Philip Twumasi‑Ankrah15, Sophie Wildsmith16, Asud Khaliq15, 
Giovanni Melillo15 and Norah Shire15
Abstract 
Background: Programmed cell death ligand‑1 (PD‑L1) expression on tumor cells (TCs) is associated with improved 
survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although its 
role as a prognostic factor is controversial. This study investigates whether tumoral expression of PD‑L1 is a prognostic 
marker in patients with recurrent and/or metastatic (R/M) HNSCC treated with standard chemotherapy.
Methods: This retrospective, multicenter, noninterventional study assessed PD‑L1 expression on archival R/M HNSCC 
tissue samples using the VENTANA PD‑L1 (SP263) Assay. PD‑L1 high was defined as PD‑L1 staining of ≥ 25% TC, with 
exploratory scoring at TC ≥ 10% and TC ≥ 50%. The primary objective of this study was to estimate the prognostic 
value of PD‑L1 status in terms of overall survival (OS) in patients with R/M HNSCC.
Results: 412 patients (median age, 62.0 years; 79.9% male; 88.2% Caucasian) were included from 19 sites in seven 
countries. 132 patients (32.0%) had TC ≥ 25% PD‑L1 expression; 199 patients (48.3%) and 85 patients (20.6%) had 
TC ≥ 10% and ≥ 50%, respectively. OS did not differ significantly across PD‑L1 expression (at TC ≥ 25% cutoff median 
OS: 8.2 months vs TC < 25%, 10.1 months, P = 0.55) or the ≥ 10% and ≥ 50% cutoffs (at TC ≥ 10%, median OS: 
9.6 months vs TC < 10%, 9.4 months, P = 0.32, and at TC ≥ 50%, median OS 7.9 vs TC < 50%, 10.0 months, P = 0.39, 
respectively).
Conclusions: PD‑L1 expression, assessed using the VENTANA PD‑L1 (SP263) Assay, was not prognostic of OS in 
patients with R/M HNSCC treated with standard of care chemotherapies.
Trial registration ClinicalTrials.gov, NCT02543476. Registered September 4, 2015.
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Background
Approximately 60% of patients with head and neck 
squamous cell carcinoma (HNSCC) are diagnosed 
with locally advanced disease, which has a 5-year over-
all survival (OS) rate of approximately 30% [1]. Most 
patients with HNSCC will eventually experience either 
local or distant recurrence [2], while approximately 
10% of patients with HNSCC will initially present with 
metastatic disease [3]. Patients with recurrent and/
or metastatic (R/M) HNSCC have historically had a 
poor prognosis [4]. Traditional standard of care for 
first-line therapy in patients with R/M HNSCC is plat-
inum-based chemotherapy plus cetuximab and 5-fluo-
rouracil [5, 6], yielding a median OS of approximately 
10  months [7]. However, this is usually only appropri-
ate for patients who have an acceptable Eastern Coop-
erative Oncology Group performance status (ECOG 
PS) and are able to tolerate platinum-based therapy. 
Patients with R/M HNSCC treated in the second-line 
setting have a poorer prognosis, with median OS of 
approximately 4–8  months [3, 8, 9]. Standard therapy 
in this setting includes single-agent therapies (e.g. 
methotrexate, docetaxel, or cetuximab) which yield 
objective response rates (ORRs) of 4–13% in the plat-
inum-refractory setting [3, 8, 9]. More recently, phase 
III studies have demonstrated that immuno-oncology 
(IO) agents targeting programmed cell death-1 (PD-
1)/programmed cell death ligand-1 (PD-L1) improve 
OS in both the first-line and second-line settings, 
with median OS of approximately 13–15  months and 
7–8 months, respectively [10–14].
PD-L1 is expressed on antigen-presenting cells and 
other immune cells (ICs) and is upregulated on HNSCC 
tumor cells (TCs) [15, 16]. The presence of PD-L1 can 
be readily detected by immunohistochemistry (IHC) 
staining [16]. Evidence is building that PD-L1 expres-
sion on TCs is associated with improved survival in 
patients with HNSCC treated with IO agents and yet 
the role of PD-L1 in outcomes irrespective of treatment 
(i.e. prognosis) is still unclear, with conflicting reports 
of PD-L1 as both a negative and positive prognostic 
factor [17–23]. Therefore, the SUPREME-HN study 
was conducted to investigate the possible prognostic 
role PD-L1 expression on TCs has in patients with R/M 
HNSCC. Here, we describe patient characteristics, OS, 
and other clinical outcomes related to PD-L1 expres-
sion independent of treatment choice [20, 24].
Methods
Study design
SUPREME-HN was a retrospective, international, mul-
ticenter, noninterventional cohort study based on data 
derived from established medical records and analysis 
of archival tumor samples (ClinicalTrials.gov identi-
fier: NCT02543476); for the purposes of this study and 
for patient selection, the index date was defined as the 
date of diagnosis of R/M disease not amenable to local 
therapy.
Patient population
Patients aged ≥ 18  years with histologically confirmed 
HNSCC of the oral cavity (tongue, gum, floor of mouth, 
or other/unspecified part of the mouth), oropharynx, lar-
ynx, or hypopharynx were eligible if they had R/M dis-
ease not amenable to local therapy with curative intent 
(surgery, radiation therapy, chemo-radiation). Patients 
with locally advanced disease amenable to curative local 
therapy were excluded as were patients who had received 
prior IO treatment with anti-cytotoxic T-lymphocyte-
associated antigen 4, or anti-PD-1, anti-PD-L1, or anti-
PD-L2 antibodies for HNSCC.
Procedures
Archival tumor samples (< 5  years old) were obtained 
anytime during the disease history from patients who 
were diagnosed between March 1, 2011 and June 30, 
2015. Biopsies or resections from the primary site, lymph 
node, or distant metastatic sites were provided for analy-
sis as formalin-fixed, paraffin-embedded (FFPE) blocks 
or sections < 60 days old.
For patients with more than one tissue sample, the 
most recent sample from the index date was used to 
determine PD-L1 expression. PD-L1 IHC staining of 
FFPE tissue samples was performed using the VENTANA 
PD-L1 (SP263) Assay on the automated Ventana Bench-
Mark ULTRA ® platform (Ventana Medical Systems Inc., 
Tucson, AZ, USA) [25]. PD-L1 expression was scored by 
pathologists trained by the manufacturer, at an approved 
central testing laboratory. PD-L1 expression was evalu-
ated for a cutoff of ≥ 25% of TCs with membrane stain-
ing for PD-L1 at any intensity (TC ≥ 25%). Exploratory 
scoring was assessed at TC ≥ 10% and TC ≥ 50%. Patient 
characteristics were collected including ECOG PS at the 
index date, smoking habits, alcohol consumption, human 
papilloma virus (HPV) status, HIV status, and medical 
Keywords: Biomarker, Head and neck squamous cell carcinoma, Immuno‑oncology, PD‑L1, Programmed cell death 
ligand‑1, Prognosis
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history. Tumor characteristics, treatment patterns, and 
outcome measures were recorded.
Study endpoints
The study primary endpoint was OS as defined from the 
date of diagnosis of R/M HNSCC (index date) to time of 
death due to any causes. OS was reported separately in 
predefined subgroups based on baseline characteristics 
(e.g. HPV status, anatomical site of tumor). Secondary 
endpoints included descriptive analyses of demograph-
ics and clinical characteristics distribution with PD-L1 as 
well as investigator-assessed ORR, duration of response, 
and progression-free survival (PFS). ORR (complete 
response + partial response) was based on Response 
Evaluation Criteria In Solid Tumors (RECIST) v1.1. PFS 
was assessed from the start of first-line therapy for R/M 
disease to progression on or after therapy, or death due 
to any cause (whichever came first), and from the start of 
second-line therapy to first documented disease progres-
sion or death due to any cause (whichever came first).
Statistical analyses
The sample size to support the primary endpoint was 
not known a priori and was driven by the number of 
patients at selected sites with available tissue samples. 
Based on assumptions of a PD-L1 high prevalence of 25% 
(TC ≥ 25%), a median OS of 10 months, uniform accrual 
over 52 months with 10 months’ follow-up from the last 
patient entering, and exponentially distributed survival 
times, it was determined post hoc that the study statistics 
could be powered to the 80% level (two-sided alpha 0.05) 
to detect a hazard ratio (HR) of 0.7 for PD-L1 high versus 
low/negative patients for a total of 396 patients and 278 
deaths.
Time-to-event endpoints were described using the 
Kaplan–Meier method. Two-sided 95% confidence inter-
vals (CIs) were provided for the main statistical estima-
tors. OS and PFS were compared between patients with 
PD-L1 high and low/negative expression for the different 
cutoffs using a log-rank test at a 5% level of significance. 
Prognostic value of PD-L1 expression in terms of OS was 
investigated using a multivariable Cox proportional haz-
ards model where covariates were selected by biological 
and clinical significance and included age, race, smoking 
status, alcohol use, metastatic disease, platinum-based 
therapy, and anatomical site as baseline covariates. Due 
to the retrospective design of the study, some data were 
unavailable for collection.
Results
Baseline characteristics
Nineteen sites in seven countries screened 513 patients 
with R/M HNSCC tumors not amenable to local therapy 
(e.g. surgery or radiation) or at stage IVC between March 
1, 2011 and June 30, 2015. The majority of patients 
(n = 213; 51.7%) were from the United States, with the 
remainder from Greece (n = 57; 13.8%), Spain (n = 49; 
11.9%), Germany (n = 35; 8.5%), Italy (n = 33; 8.0%), Japan 
(n = 15; 3.6%), and South Korea (n =10; 2.4%). Of the 513 
patients, 412 met all eligibility criteria and comprised 
the full analysis set; PD-L1 expression was unknown in 
16 (3.9%). The 16 patients with unknown PD-L1 expres-
sion were not included in prevalence assessments or out-
come assessments unless otherwise stated. Most patients 
(n =400; 97.1%) provided one tissue sample, with 12 
patients providing two samples for a total of 424 tissue 
samples. For patients who provided two samples, PD-L1 
expression was determined independently on each sam-
ple, and the sample obtained closest to the index date was 
used to assess PD-L1 expression. Tumor samples were 
obtained from the primary site in 162/424 cases (38.2%), 
from recurrent disease in 179/424 cases (42.2%), and 
from distant sites in 83/424 cases (19.6%).
The median age of patients at or closest to the index 
date was 62.0 years (range 28.0–93.0; n = 411) (Table 1). 
There were 132 patients (32.0%) who were found to have 
TC ≥ 25% PD-L1 expression (Table  1) [26–28]. Further-
more, 199 patients (48.3%) and 85 patients (20.6%) had 
TC ≥ 10% and ≥ 50%, respectively. Among 130 patients 
with HPV data, 37 were HPV-positive (28.5%). Of the 
HPV-positive patients, 8 (21.6%) had TC ≥ 25% PD-L1 
expression, 17 (45.9%) had TC ≥ 10% PD-L1 expression, 
and 5 patients (13.5%) had TC ≥ 50% PD-L1 expression.
At TC ≥ 25%, the PD-L1 prevalence was higher among 
females (43.0% vs 30.9% for males), Asians (50.0% vs 
32.7% and 30.0% for Caucasians and Black/African 
Americans, respectively), ECOG PS 0 (50.7% vs 32.2% 
and 26.8% for 1 and ≥ 2, respectively), and never smokers 
(42.3% vs 26.8% and 32.2% for current and former smok-
ers, respectively) (Table 1). PD-L1 prevalence decreased 
with increasing ECOG PS values and was highest in 
never smokers (compared with current and former smok-
ers) and former alcohol users (vs current).
HNSCC tumor characteristics
The most common sites from which tumor samples were 
collected were oral cavity (35.0%; n = 143), larynx (33.5%; 
n = 137), and oropharynx (22.2%; n = 91). Oral cavity 
tumors (43.5%) showed the highest prevalence of PD-L1 
expression (TC ≥ 25%), while the hypopharynx tumors 
were most often associated with PD-L1 < 25% (90.5%) 
(Table 1).
The prevalence of PD-L1 expression TC ≥ 25% was 
similar irrespective of whether the sample was collected 
from the primary tumor (34.0%), or recurrent (32.6%) 
or metastatic (33.8%) sites. There was also no difference 
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Table 1 Prevalence of PD-L1 expression based on baseline characteristics and HNSCC tumor characteristics
Characteristic, % Na PD-L1 TC ≥ 25% (n = 132) PD-L1 TC < 25% (n = 264)
Median age, years (range) 62.0 (38.0–87.0) 62.0 (28.0–93.0)
  < 60 167 32.9 67.1
  ≥ 60 228 33.8 66.2
Sex
 Male 317 30.9 69.1
 Female 79 43.0 57.0
Race
Caucasian 339 32.7 67.3
 Black or African American 20 30.0 70.0
 Asian 22 50.0 50.0
Region
 United States 205 29.3 70.7
 Asia 22 50.0 50.0
 Europe 169 36.1 63.9
ECOG PS
 0 73 50.7 49.3
 1 87 32.2 67.8
  ≥ 2 41 26.8 73.2
Tobacco use
 Current 97 26.8 73.2
 Former 199 32.2 67.8
 Never 78 42.3 57.7
Alcohol consumption
 Current 148 26.4 73.6
 Former 123 32.5 67.5
HPV status
 Positive 37 21.6 78.4
 Negative 93 25.8 74.2
Timing of tissue sample extraction
 Pre‑1st chemotherapy, % 202 30.2 69.8
 Post‑1st chemotherapy, % 36 25.0 75.0
Type of tumor sample
 Surgical resection 186 34.9 65.1
 Surgical biopsy 199 32.2 67.8
 Punch biopsy 8 12.5 87.5
Location of tumor sample
 Primary tumor 153 34.0 66.0
 From recurrent disease 175 32.6 67.4
 From metastatic disease 80 33.8 66.3
Primary tumor site 132 261
 Oral cavity 108 43.5 56.5
 Oropharynx 61 34.4 65.6
 Hypopharynx 21 9.5 90.5
 Larynx 99 30.3 69.7
 Overlapping lesion 22 22.7 77.3
Stage at index  dateb
 Stage 0–III 17 29.4 70.6
 Stage IVA 62 37.1 62.9
 Stage IVB 21 23.8 76.2
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in prevalence regarding the type of tumor sample used 
(34.9% in surgical resection vs 32.2% for surgical biopsy) 
(Table 1).
Treatment history
Among the total cohort of 412 patients, 238 patients 
(57.8%) received first-line chemotherapy and 84 patients 
(20.4%) received additional second-line chemother-
apy after the index date (Table  2). A limited number of 
patients received subsequent lines of chemotherapy 
(n = 42; 10.2%). First-line chemotherapy was adminis-
tered to 52.3% of patients in the PD-L1 TC ≥ 25% group 
and 60.2% in the PD-L1 TC < 25% group. Approximately 
30% of patients underwent palliative surgical interven-
tions and another ~ 30% underwent radiotherapy. The 
most common first-line targeted therapy was cetuxi-
mab (49.6%), and chemotherapy treatments were cispl-
atin (44.7%), 5-fluorouracil (36.5%), carboplatin (31.6%), 
paclitaxel (25.2%), and docetaxel (16.2%) (Table  2). The 
rates of prior first-line treatment with cetuximab and 
platinum-based therapy were similar for patients in 
either PD-L1 cohort. The most common second-line tar-
geted therapy was cetuximab (33.3%), and chemother-
apy treatments included paclitaxel (27.8%), carboplatin 
(22.2%), docetaxel (20.0%), and 5-fluorouracil (11.1%), 
again with no differences between PD-L1 expression 
cohorts (Table 2).
Treatment outcomes
A total of 290 (70.4%) patients died during the study 
period. Median OS from the index date of R/M dis-
ease was 9.6  months (95% CI 8.3–10.8). Among the 
patients with known PD-L1 expression, OS did not dif-
fer significantly for PD-L1 TC ≥ 25% versus TC < 25% 
(median 8.2 vs 10.1 months, P = 0.55; Fig. 1a). This was 
also true for PD-L1 expression cutoffs of TC ≥ 10% 
versus TC < 10% (median 9.6 vs 9.4  months, P = 0.32; 
Fig. 1b) and TC ≥ 50% versus TC < 50% (median 7.9 vs 
10.0 months, P = 0.39; Fig. 1c). Among the 130 patients 
with available HPV status, median OS was 10  months 
(95% CI 5.1–16.9) in patients with HPV-positive status 
and 8.3 months (95% CI 5.8–12.5) in those with HPV-
negative status. There was no association of HPV status 
with PD-L1 expression.
The estimated median OS was 8.0  months (95% CI 
6.3–10.0) in patients with oral cavity primary tumor 
site (n =143), 10.4  months (95% CI 6.9–14.9) in oro-
pharynx (n =91), 12.5  months (95% CI 8.9–14.8) in 
larynx (n =137), 12.2  months (95% CI 5.7–21.0) in 
hypopharynx (n =27), and 4.0  months (95% CI 3.3–
14.7) in patients with overlapping regions (n =11). The 
OS for patients with oral cavity tumors was numeri-
cally lower in the PD-L1 TC ≥ 25% population than in 
the PD-L1 TC < 25% population (median 6.9 months vs 
9.7 months; log-rank test; P = 0.15). Similarly, for oro-
pharyngeal primary site patients, those in the PD-L1 
TC ≥ 25% population had a median OS of 6.3  months 
versus 14.8 months for patients in the PD-L1 TC < 25% 
population (log-rank test; P = 0.03) (Fig.  1d). In con-
trast, numerically longer survival was seen in the PD-L1 
TC ≥ 25% population than in the PD-L1 TC < 25% pop-
ulation with hypopharyngeal primary tumors (median 
21 months vs 12.2 months; log-rank test; P = 0.35).
Table 1 (continued)
Characteristic, % Na PD-L1 TC ≥ 25% (n = 132) PD-L1 TC < 25% (n = 264)
 Stage IVC 230 31.3 68.7
Time from diagnosis to index
 Median, months (range) 11.4 (0.0–475.9) 14.7 (0.0–349.8)
Sites of new metastases post index date
 Local lymph node 89 31.5 68.5
 Lung 77 27.3 72.7
 Bone 29 37.9 62.1
 Distant lymph node 23 34.8 65.2
 Liver 23 30.4 69.6
 Skin/soft tissue 21 42.9 57.1
 Head and neck 11 27.3 72.7
 Pleura 9 44.4 55.6
a Patients with PD-L1 result N = 396
b Index date is defined as date of diagnosis of R/M HNSCC not amenable to local therapy
ECOG PS Eastern Cooperative Oncology Group performance status, HNSCC head and neck squamous cell carcinoma, HPV human papilloma virus, mo months, PD-L1 
programmed cell death-ligand 1, R/M recurrent and/or metastatic, TC tumor cell
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Median PFS from the start of first- and second-line 
chemotherapy was 4.6  months (95% CI 4.0–5.0) and 
2.8 months (95% CI 1.9–4.4), respectively. The PFS from 
the start of first-line chemotherapy did not differ signifi-
cantly among patients with TC ≥ 25% PD-L1 expression 
versus TC < 25% (median: 4.2 vs 4.8  months, P = 0.37) 
(Fig. 2a). This was similar when TC ≥ 10% PD-L1 expres-
sion versus TC < 10% and TC ≥ 50% PD-L1 expression 
versus TC < 50% cutoff values were applied (median 4.4 
vs 4.9 months, P = 0.544 and median 4.8 vs 4.5 months, 
P = 0.557, respectively). However, median PFS from 
the start of second-line chemotherapy was signifi-
cantly different between patients with TC ≥ 25% PD-L1 
(n = 25) expression versus those with TC < 25% (n = 58) 
(4.1 months vs 2.2 months, P = 0.04). The difference was 
also significant for patients with TC ≥ 10% PD-L1 (n = 38) 
expression versus those with TC < 10% (n = 45) (4.1 vs 
2.1  months, P = 0.04) and those patients with TC ≥ 50% 
PD-L1 (n = 13) expression versus those with TC < 50% 
(n = 70) (6.3 vs 2.4  months, P = 0.03). However, these 
results must be weighed against the small sample size and 
lack of adjustment for any confounding factors (Fig. 2b). 
Validation in a larger cohort of patients is required.
Among the 98 patients who had a tumor response, 
according to RECIST, after treatment with first-line 
chemotherapy, ORR was 43.9% (95% CI 33.9–54.3). 
Patients with PD-L1-high expressing tumors (TC ≥ 25%) 
had an ORR of 40.0% (95% CI 21.1–61.3, n = 25) and 
those with TC < 25% had an ORR of 44.3% (95% CI 
32.4–56.7, n = 70) (Table  3). Among the 30 patients 
treated with second-line chemotherapy who had a tumor 
response evaluated, the ORR was 13.3% (95% CI 3.8–
30.7). The ORR observed for the TC ≥ 25% cohort was 
20.0% (2/10 patients; 95% CI 2.5–55.6) and those with 
TC < 25% had an ORR of 5.6% (1/18 patients; 95% CI 0.1–
27.3) (Table 3).
Multivariable risk factor analyses
PD-L1 expression TC ≥ 25%, was not identified as a sig-
nificant predictor of risk of death, with an HR of 1.04 
(95% CI 0.79–1.37; P = 0.79), nor were cutoffs TC ≥ 10% 
and TC ≥ 50% (HR 0.86; 95% CI 0.67–1.11; P = 0.25 
and HR 1.14; 95% CI 0.83–1.56; P = 0.42, respectively) 
(Fig. 3; Table 4). Metastatic disease at the time of index 
date was associated with increased risk of death, whereas 
age ≥ 60  years, platinum-based therapy, and anatomic 
Table 2 Treatment history
a Patients with PD-L1 result N = 396
PD-L1 programmed cell death-ligand 1, TC tumor cell
Treatment history, n (%) PD-L1 TC ≥ 25%
(n = 132a)
PD-L1 TC < 25%
(n = 264a)
Total (N = 412)
Palliative surgical interventions 44 (33.3) 74 (28.0) 123 (29.9)
Radiotherapy 43 (32.6) 63 (23.9) 113 (27.4)
Chemoradiation therapy 1 (0.8) 0 (0.0) 1 (0.2)
Line of chemotherapy, n 132 264 412
 1st 69 (52.3) 159 (60.2) 238 (57.8)
 2nd 24 (18.2) 55 (20.8) 84 (20.4)
  ≥ 3rd 8 (6.1) 28 (10.6) 42 (10.2)
Type of first‑line chemotherapy, n 77 177 266
 Cetuximab 38 (49.4) 91 (51.4) 132 (49.6)
 Cisplatin 41 (53.2) 71 (40.1) 119 (44.7)
 Carboplatin 15 (19.5) 64 (36.2) 84 (31.6)
 Paclitaxel 10 (13.0) 56 (31.6) 67 (25.2)
 Docetaxel 18 (23.4) 22 (12.4) 43 (16.2)
 5‑Fluorouracil 35 (45.5) 56 (31.6) 97 (36.5)
Type of second‑line chemotherapy 25 60 90
 Cetuximab 8 (32.0) 21 (35.0) 30 (33.3)
 Cisplatin 1 (4.0) 4 (6.7) 5 (5.6)
 Carboplatin 6 (24.0) 13 (21.7) 20 (22.2)
 Paclitaxel 5 (20.0) 20 (33.3) 25 (27.8)
 Docetaxel 7 (28.0) 10 (16.7) 18 (20.0)
 5‑Fluorouracil 5 (20.0) 5 (8.3) 10 (11.1)
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a
b
c
d
Fig. 1 Overall survival (OS) by PD‑L1  expressiona. aPatients with PD‑L1 result n = 396: a TC ≥ 25%, b TC ≥ 10%, and c TC ≥ 50%; d oropharynx 
anatomical sub‑site (n = 91) by PD‑L1 status
Page 8 of 14Pai et al. J Transl Med          (2019) 17:429 
subsite of larynx were associated with a lower risk of 
death regardless of the PD-L1 cutoff used (Fig. 3; Table 4). 
Discussion
In this study, we investigated if PD-L1 expression was 
associated with survival in patients treated with standard 
chemotherapy.
In the entire population of this study, PD-L1 was not 
prognostic for survival in patients with HNSCC who 
received standard chemotherapy regimens. This finding 
was consistent with observations in randomized con-
trolled trials of similar patients with R/M HNSCC [10, 26, 
29]. In CheckMate 141, for patients treated with inves-
tigator’s choice the median OS in PD-L1 TC ≥ 1% was 
slightly lower than in PD-L1 TC < 1% [4.6  months (95% 
CI 3.8–5.8) vs 5.8 months (95% CI 4.0–9.8)] [30]. In KEY-
NOTE-040 the survival of patients treated with investiga-
tor’s choice of standard of care (methotrexate, docetaxel, 
or cetuximab) did not increase with increasing PD-L1 
expression [12]. Similar results have also been observed 
a
b
Fig. 2 PFS by PD‑L1 expression. a From start of first‑line chemotherapy (n = 242) and b second‑line chemotherapy (n = 83)
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in an evaluation of commercially obtained patient sam-
ples with stage I–IV HNSCC, in which PD-L1 expression 
was not prognostic for OS based on a TC ≥ 25% cutoff 
[31].
Currently accepted prognostic markers in HNSCC 
include HPV status in patients with oropharyngeal car-
cinoma and smoking status [32]. Other researchers have 
identified prognostic factors including age, race, ECOG 
PS, prior treatments [33], C-reactive protein, leukocyte 
levels, and time from diagnosis to relapse [34]. In a mul-
tivariable analysis of the SUPREME-HN study we found 
age, platinum therapy, primary tumor location, and met-
astatic disease to be associated with survival. It is not sur-
prising that metastatic disease is associated with poorer 
survival, this variable has been incorporated in prognos-
tic models of survival in advanced cancers [35]. Similarly, 
patients healthy enough to tolerate a platinum-based 
therapy might be expected to survive longer. The obser-
vation here of improved survival in older patients 
(≥ 60  years) compared with younger patients is some-
what counterintuitive; it is generally considered that 
older adults have comparable survival outcomes but 
with increased toxicity [36]. However, a non-significantly 
higher survival in patients > 65 years versus < 65 years has 
also been shown in patients treated with investigator’s 
choice in a retrospective analysis of CheckMate 141 [37]. 
In both the SUPREME-HN and the CheckMate 141 stud-
ies, investigator’s choice of standard of care was used. It is 
possible that elderly patients were treated with taxanes, 
rather than cisplatin and cetuximab, due to the higher 
toxicities associated with the latter therapies. Later pub-
lications have indicated that docetaxel improves OS over 
cisplatin [38]. One could speculate that investigators 
selected therapies for older patients based on the toxicity 
Table 3 Response and survival by PD-L1 expression
a Patients with PD-L1 result N = 396
b ORR measured by RESIST
ORR objective response rate, OS overall survival, PD-L1 programmed cell death-ligand 1, PFS progression-free survival, RECIST Response Evaluation Criteria In Solid 
Tumors
Endpoint, na (%) PD-L1 TC ≥ 25% PD-L1 TC < 25% PD-L1 TC ≥ 10% PD-L1 TC < 10% PD-L1 TC ≥ 50% PD-L1 TC < 50%
From diagnosis date to death
 Median OS, months (range) 8.2 (6.3–10.6) 10.1 (8.3–12.2) 9.6 (7.5–12.5) 9.4 (7.9–11.4) 7.9 (5.5–12.4) 10.0 (8.5–11.8)
 log‑rank P value, PD‑L1 high vs 
PD‑L1 low/negative
0.55 0.32 0.39
From first‑line therapy
 Number evaluable 25 70
 ORRb, n (%)
 Overall response rate 10 (40.0) 31 (44.3)
 Complete response 0 (0.0) 1 (1.4)
 Partial response 10 (40.0) 30 (42.9)
 Duration of response, n 8 24
 Median, weeks (range) 10.6 (0.1–28.7) 15.3 (1.7–52.3)
 PFS, n 73 169 110 132 41 201
Median, months (range) 4.2 (2.6–4.8) 4.8 (3.9–5.8) 4.4 (3.3–4.9) 4.9 (3.9–6.0) 4.8 (3.2–6.1) 4.5 (3.9–5.0)
log‑rank P value, PD‑L1 high vs PD‑L1 
low/negative
0.37 0.54 0.56
From second‑line therapy
 Number evaluable 10 18
 ORRb, n (%)
 Overall response rate 2 (20.0) 1 (5.6)
 Complete response 0 (0.0) 0 (0.0)
 Partial response 2 (20.0) 1 (5.6)
 Duration of response, n 2 1
 Median, weeks (range) 10.6 (5.9–15.4) 1.3 (1.3–1.3)
 PFS, n 25 58 38 45 13 70
 Median, months (range) 4.1 (2.8–7.1) 2.2 (1.6–4.0) 4.1 (2.2–6.5) 2.1 (1.6–3.6) 6.3 (1.2–13.8) 2.4 (1.6–3.8)
 log‑rank P value, PD‑L1 high vs 
PD‑L1 low/negative
0.04 0.04 0.03
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Fig. 3 Multivariable analysis of risk factors for OS. aPatients with OS data n = 370, patients with PD‑L1 result n = 355
Table 4 Multivariable analysis of risk factors for analyses examining PFS or OS for all-comers
Statistically significant P values are in italics
a Patients with PD-L1 result N = 396
CI confidence interval, HR hazard ratio, OS overall survival, PD-L1 programmed cell death ligand-1, PFS progression-free survival
Category PFS from start of first-line 
therapy (n = 253)
PFS from start of second-line 
therapy (n = 88)
OS from index date (n = 370)
HR 95% CI P value HR 95% CI P value HR 95% CI P value
PD‑L1 expression high vs  lowa 1.09 (0.78–1.52) 0.63 0.58 (0.30–1.13) 0.11 1.04 (0.79–1.37) 0.790
Age < 60 vs ≥ 60 years 0.89 (0.67–1.18) 0.40 0.82 (0.45–1.47) 0.50 0.71 (0.55–0.92) 0.008
Race Caucasian vs other 0.59 (0.38–0.9) 0.02 0.61 (0.30–1.23) 0.16 0.92 (0.62–1.37) 0.689
Nonsmoker vs current/former smoker 0.81 (0.55–1.21) 0.31 0.97 (0.47–2.01) 0.93 1.20 (0.85–1.69) 0.292
Heavy alcohol use, no vs yes 0.97 (0.57–1.66) 0.90 1.11 (0.39–3.14) 0.85 1.33 (0.80–2.19) 0.268
Metastatic disease, no vs yes 1.27 (0.96–1.68) 0.10 0.59 (0.34–1.03) 0.06 1.42 (1.10–1.84) 0.008
Platinum‑based therapy, no vs yes 1.10 (0.68–1.79) 0.70 3.084 (0.64–14.81) 0.16 0.70 (0.52–0.94) 0.018
Anatomical site vs oral cavity
 Oropharynx 0.89 (0.59–1.35) 0.58 0.88 (0.39–1.99) 0.75 0.74 (0.52–1.05) 0.089
 Hypopharynx 0.65 (0.36–1.17) 0.15 0.72 (0.30–1.75) 0.47 0.62 (0.36–1.05) 0.076
 Larynx 0.74 (0.51–1.06) 0.10 0.88 (0.44–1.76) 0.72 0.63 (0.46–0.86) 0.003
 Overlapping lesion 1.05 (0.47–2.33) 0.91 0.82 (0.16–4.10) 0.81 1.25 (0.65–2.38) 0.503
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profile, which were later demonstrated to be more effica-
cious. Urba identified race (Caucasian vs other) as prog-
nostic for OS and PFS. In the SUPREME-HN study an 
association was observed that was only significant for 
PFS from first-line therapy; possibly because there was 
a smaller non-Caucasian population in this study. In a 
univariate analysis, Urba identified primary tumor loca-
tion as negatively prognostic for survival (oral cavity vs 
“other”, HR 1.37, 95% CI 1.15–1.63, P = 0.01) and associ-
ated with reduced PFS [33]. In the multivariable analysis 
of the SUPREME-HN study, patients with primary tumor 
locations of oropharynx and hypopharynx had improved 
OS compared with patients with oral cavity carcinoma 
and survival was significantly longer in patients with 
tumors in laryngeal versus oral cavity sites (HR 0.63, 95% 
CI 0.46–0.86, P = 0.003). Currently smoking and HPV 
status are considered to be major independent prognos-
tic factors in patients with oropharyngeal cancer [32] and 
recent HNSCC randomized clinical trial studies have 
been stratified using PD-L1 and HPV, smoking status, 
and performance status [39]. The SUPREME-HN study 
shows meaningful survival differences by primary tumor 
location, raising the question whether site of tumor ori-
gin should also be considered in study design and patient 
treatment.
The PD-L1 prevalence at TC ≥ 25% was consistent 
across biopsy locations: 32.1% (primary tumor), 31.8% 
(recurrent site), and 32.5% (metastatic site). These data 
suggest that any tumor lesion can be used for PD-L1 test-
ing for HNSCC, although in this study the primary and 
metastatic lesions were not from the same patient. Addi-
tionally, PD-L1 expression seems to be stable across the 
primary versus metastatic setting, only the punch biopsy 
gave lower PD-L1 expression.
The prevalence of PD-L1 varied according to a number 
of other factors; gender (higher in females), race, region, 
ECOG PS 0, oral cavity cancers, and never smokers. High 
PD-L1 prevalence has previously been significantly asso-
ciated with females, never smokers, and oral cavity in 
other studies of second-line patients with HNSCC [23]. 
The PD-L1 TC ≥ 25% prevalence varied substantially 
depending on the primary tumor location; from 43.5% in 
oral cavity to 9.5% in hypopharyngeal (see Table 1). The 
median OS for patients with oral cavity carcinoma was 
lower in PD-L1 TC ≥ 25% than PD-L1 TC < 25% patients; 
poor prognosis in PD-L1 TC ≥ 25% oral cavity patients 
has been observed by others [18]. Likewise, for oro-
pharyngeal primary site patients, median OS in patients 
with PD-L1 TC ≥ 25% was less than that seen for patients 
with PD-L1 TC < 25% (log-rank test; P = 0.03; Fig.  1d). 
Conversely, longer survival was seen in PD-L1 TC ≥ 25% 
than PD-L1 TC < 25% patients with hypopharyngeal pri-
mary tumors (21  months vs 12.2  months). These data 
indicate that for patients with tumors of oral cavity 
and oropharyngeal origin, PD-L1 expression is linked 
to shorter survival, whereas those with PD-L1 high 
hypopharyngeal primary tumors live longer.
Therefore, although PD-L1 was not prognostic in the 
entire SUPREME-HN cohort, our data indicate PD-L1 
can be both positively and negatively prognostic depend-
ing on the primary tumor location. This finding may help 
to explain historical conflicting views of the prognos-
tic value of PD-L1; for example, the finding that PD-L1 
expression was positively prognostic in laryngeal squa-
mous cell carcinoma [22] but conversely associated with 
poor prognosis in oral squamous cell carcinoma [17].
Study limitations pertain mainly to the retrospec-
tive study design, and hence, the reliance of available 
information in medical charts. Quantitative analyses of 
risk factors were limited due to missing information on 
performance status, HPV status, and small sample size. 
This study used an assay validated for PD-L1 expression 
on TCs and did not investigate the prognostic value of 
IC PD-L1 expression. PD-L1 expression in other cellu-
lar compartments of the tumor microenvironment may 
be indicative of survival. The variety of scoring methods 
used for determining PD-L1 positivity (TCs and/or ICs) 
may also contribute to the apparent contradictory publi-
cations regarding its prognostic value.
Tumor stage and grade at initial diagnosis were not 
available for all patients since they may have received 
initial care in a hospital other than the investigating site. 
Furthermore, the definition of R/M status may have led 
to the exclusion of patients who received local therapies 
for palliative purposes, as the treatment intent was not 
always mentioned in the patient’s medical records. Addi-
tionally, evaluations of tumor response and progression 
were not evaluated via blinded, independent commit-
tee review as would be the case in clinical trials, which 
can lead to some variability in results. PD-L1 expression 
was assessed using available tissue that was not neces-
sarily obtained at the time of initial diagnosis or at the 
same stage of disease for all patients. Findings from addi-
tional exploratory analyses suggest that PD-L1 expres-
sion was lower in tissue samples obtained after a patient’s 
prior exposure to chemotherapy than prior to initiation 
of chemotherapy, irrespective of tissue origin (primary 
tumor, recurrent site, or metastatic site). A similar find-
ing was observed for the subset of samples from the pri-
mary tumor obtained after exposure to radiotherapy.
Since starting the SUPREME-HN study a number of 
immunotherapies have been approved for use in R/M 
HNSCC. The approvals of PD-L1 assays as compan-
ion diagnostics demonstrates the predictive nature and 
the value of this biomarker. As the use of immunother-
apy increases the opportunity diminishes to perform a 
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prospective study in patients treated with non-immune 
based treatments and thus SUPREME-HN represents a 
unique historical record of the prognostic value of PD-L1.
Conclusion
There have been conflicting results reported regarding 
the prognostic value of PD-L1 expression on TCs. Early 
reports did not demonstrate any association between 
PD-L1 expression and OS, whereas other studies have 
suggested that PD-L1 expression may be associated with 
improved survival [17–23]. In the SUPREME-HN study, 
PD-L1 expression using TCs at cutoff values of 10%, 25%, 
and 50% was not prognostic for survival in patients with 
HNSCC treated with standard therapies; however, PD-L1 
expression may be positively or negatively prognostic 
when anatomic subsites within the head and neck are 
considered.
In evaluating the correlation of PD-L1 and survival, 
previous studies did not always account for confounding 
factors. Based on our analysis these factors, specifically 
HPV status, primary tumor location, and demographic 
factors, may be highly relevant to OS in patients with 
R/M HNSCC.
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